Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus
Summary
Diabetes mellitus (DM) is a complex metabolic disorder characterized by hyperglycemia and abnormalities in carbohydrate, fat, and protein metabolism. Despite the advancement in anti-diabetic drug therapy, most patients fail to achieve optimal glycemic control. This highlights the need for more effective strategies to control type 2 diabetes mellitus. Nitazoxanide (NTZ), a broad-spectrum anti-infective drug with activity against various protozoa, helminthes, bacteria, and viruses, was identified as peroxisome proliferative activated receptor gamma (PPARγ) agonist using one dimensional drug profile matching. Additionally, it improved insulin sensitivity in insulin-resistant type 2 diabetic rats. Therefore, this study is designed to evaluate the efficacy of nitazoxanide as adjunctive therapy in patients with type 2 diabetes mellitus.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2024-10-01
- Completion
- 2025-01-01
Outcome
Missed primary endpoint
paper HbA1c, fasting blood glucose, insulin, asprosin, and MDA were not considerably different between the two groups. PMID 40815384 ↗
paper CONCLUSION: NTZ may alleviate oxidative stress and inflammation in type 2 diabetes despite no improvement in glycemic parameters. PMID 40815384 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitazoxanide | Other / unclassified | 500 mg | Oral |